Strategies To Slow Generic Drug Entries Include Early Patent Activity
This article was originally published in The Tan Sheet
Executive Summary
Brand name manufacturers' early announcements of patent activity may deter generic companies as they consider opportunities and risks prior to patent expirations, A.T. Kearney VP-Pharmaceutical Practice Richard Findlay told a Food & Drug Law Institute conference on the Waxman/Hatch Act Nov. 23.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning